Hydroxyurea as an inhibitor of hepatitis C virus RNA replication
- PMID: 20204428
- DOI: 10.1007/s00705-010-0624-1
Hydroxyurea as an inhibitor of hepatitis C virus RNA replication
Abstract
Hepatitis C virus (HCV) is the main causative agent of chronic liver disease, which may develop into liver cirrhosis and hepatocellular carcinoma. By using a recently developed reporter assay system in which genome-length HCV RNA replicates efficiently, we found that hydroxyurea (HU), a DNA synthesis inhibitor, inhibited HCV RNA replication. Moreover, we demonstrated that the anti-HCV activity of the combination of IFN-alpha and HU was higher than that of IFN-alpha alone. These results suggest that HU may be an effective anti-HCV reagent that can be used not only singly but also in combination with IFN-alpha to treat chronic hepatitis C.
Similar articles
-
Hydroxyurea suppresses HCV replication in humans: a Phase I trial of oral hydroxyurea in chronic hepatitis C patients.Antivir Ther. 2010;15(8):1179-83. doi: 10.3851/IMP1668. Antivir Ther. 2010. PMID: 21149925 Clinical Trial.
-
Inhibition of intracellular hepatitis C virus replication by nelfinavir and synergistic effect with interferon-alpha.J Viral Hepat. 2009 Jul;16(7):506-12. doi: 10.1111/j.1365-2893.2009.01102.x. Epub 2009 Mar 3. J Viral Hepat. 2009. PMID: 19302339
-
Gene expression associated with interferon alfa antiviral activity in an HCV replicon cell line.Hepatology. 2003 May;37(5):1180-8. doi: 10.1053/jhep.2003.50184. Hepatology. 2003. PMID: 12717400
-
Chemical genetics approach to hepatitis C virus replication: cyclophilin as a target for anti-hepatitis C virus strategy.Rev Med Virol. 2007 Jul-Aug;17(4):245-52. doi: 10.1002/rmv.534. Rev Med Virol. 2007. PMID: 17299803 Review.
-
HCV-hepatocellular carcinoma: new findings and hope for effective treatment.Microsc Res Tech. 2005 Nov;68(3-4):130-48. doi: 10.1002/jemt.20227. Microsc Res Tech. 2005. PMID: 16276514 Review.
Cited by
-
New preclinical antimalarial drugs potently inhibit hepatitis C virus genotype 1b RNA replication.PLoS One. 2013 Aug 30;8(8):e72519. doi: 10.1371/journal.pone.0072519. eCollection 2013. PLoS One. 2013. PMID: 24023620 Free PMC article.
-
Peg-interfon alpha-2a and low-dose ribavirin for treatment of hepatitis C virus infection in patients with sickle-cell anemia in Saudi Arabia.Ann Saudi Med. 2013 Nov-Dec;33(6):610-3. doi: 10.5144/0256-4947.2013.610. Ann Saudi Med. 2013. PMID: 24413867 Free PMC article. Clinical Trial.
-
Widespread Natural Occurrence of Hydroxyurea in Animals.PLoS One. 2015 Nov 24;10(11):e0142890. doi: 10.1371/journal.pone.0142890. eCollection 2015. PLoS One. 2015. PMID: 26600157 Free PMC article.
-
Development of a drug assay system with hepatitis C virus genome derived from a patient with acute hepatitis C.Virus Genes. 2012 Jun;44(3):374-81. doi: 10.1007/s11262-012-0712-2. Epub 2012 Jan 18. Virus Genes. 2012. PMID: 22252251
-
Oral disease-modifying antirheumatic drugs and immunosuppressants with antiviral potential, including SARS-CoV-2 infection: a review.Ther Adv Musculoskelet Dis. 2020 Sep 3;12:1759720X20947296. doi: 10.1177/1759720X20947296. eCollection 2020. Ther Adv Musculoskelet Dis. 2020. PMID: 32952617 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources